Benitec Biopharma Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Benitec Biopharma's estimated annual revenue is currently $3.1M per year.(i)
  • Benitec Biopharma's estimated revenue per employee is $155,000

Employee Data

  • Benitec Biopharma has 20 Employees.(i)
  • Benitec Biopharma grew their employee count by 11% last year.

Benitec Biopharma's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
SVP ManufacturingReveal Email/Phone
3
Executive DirectorReveal Email/Phone
4
Scientist IReveal Email/Phone
5
Senior ScientistReveal Email/Phone
6
Senior Research Associate IIReveal Email/Phone
7
Senior Research Associate IReveal Email/Phone
8
Senior ScientistReveal Email/Phone
9
ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Benitec Biopharma?

Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference (RNAi) with gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. Benitec is using its technology, called DNA-directed RNA interference (ddRNAi) to develop a pipeline of product candidates for the treatment of several chronic and life-threatening human diseases , including oculopharyngeal muscular dystrophy (OPMD) and hepatitis B. By combining the specificity and gene silencing effect of RNAi with gene therapy, ddRNAi has the potential to produce long-lasting silencing of disease-causing genes from a single administration, which could minimize the requirement for patients to take regular doses of medicine. Benitec’s objective is to become the leader in discovering, developing, clinically validating and commercializing ddRNAi-based therapeutics for a range of human diseases with high unmet clinical need or large patient populations and, as a result, provide a better life for patients with these diseases.

keywords:N/A

N/A

Total Funding

20

Number of Employees

$3.1M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M20-23%N/A
#2
$1.6M210%N/A
#3
$3.3M21-36%N/A
#4
$3.1M21-12%$101.5M
#5
$7.5M21-5%N/A